PLXNA4抗体;PLXNA4 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P12063(PLXNA4 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The PLXNA4 antibody targets plexin A4 (PLXNA4), a transmembrane receptor belonging to the plexin family, which plays critical roles in axon guidance, cell migration, and angiogenesis by interacting with semaphorin ligands. PLXNA4 consists of an extracellular SEMA domain for ligand binding, a PSI domain, and an intracellular GTPase-activating protein (GAP) domain involved in downstream signaling. It primarily binds to class 3 semaphorins (e.g., SEMA3A, SEMA3C) and forms complexes with neuropilins (NRP1/2) to regulate cellular responses. Dysregulation of PLXNA4 is implicated in neurological disorders (e.g., Alzheimer’s disease), cancer progression (e.g., glioblastoma, lung cancer), and immune dysfunction.

PLXNA4 antibodies are essential tools for studying its expression, localization, and function in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate PLXNA4’s role in neural circuit formation, tumor metastasis, and vascular remodeling. Monoclonal and polyclonal variants are available, often targeting specific domains (e.g., extracellular regions for ligand interaction studies). Recent research highlights PLXNA4 as a potential therapeutic target, driving demand for high-specificity antibodies to explore its mechanisms in disease models and preclinical drug development.